Structural requirements for TFPI-mediated inhibition of neointimal thickening after balloon injury in the rat

Arteriosclerosis, Thrombosis, and Vascular Biology

Volumn 19, Issue 10, 1999, Pages 2563-2567

  Han, Xin ^c   Girard, Thomas J ^a   Baum, Pamela ^c   Abendschein, Dana R ^c   Broze Jr , George J ^b  

^a Department of Protein Chemistry   (United States)

^b BARNES JEWISH HOSPITAL   (United States)

^c NONE

Author keywords

Angioplasty; Rat; Tissue factor pathway inhibitor

Indexed keywords

BLOOD CLOTTING FACTOR 10; BLOOD CLOTTING FACTOR 10A; BLOOD CLOTTING FACTOR 7A; THROMBOPLASTIN; TISSUE FACTOR PATHWAY INHIBITOR;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTICOAGULATION; ARTERY INTIMA PROLIFERATION; ARTICLE; BLOOD CLOTTING; BLOOD VESSEL INJURY; NONHUMAN; PERCUTANEOUS TRANSLUMINAL ANGIOPLASTY; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; RAT;

EID: 0032879138     PISSN: 10795642     EISSN: None     Source Type: Journal    
DOI: 10.1161/01.ATV.19.10.2563     Document Type: Article

References (33)

1. Ip JH, Fuster V, Isreal D, Badimon L, Badimon J, Chesebro JH. The role of platelets, thrombin and hyperplasia in restenosis after coronary angioplasty. J Am Coll Cardiol. 1991;17:77B-88B.
2. Wilcox JN. Thrombin and other potential mechanisms underlying restenosis. Circulation. 1991;84:432-435.
3. McBride W, Lange RA, Hillis LD. Restenosis after successful coronary angioplasty, pathophysiology and prevention. N Engl J Med. 1988;318: 1734-1737.
4. Ko FN, Yang YC, Huang SC, Ou JT. Coagulation factor Xa stimulates platelet-derived growth factor release and mitogenesis in cultured vascular smooth cells of rats. J Clin Invest. 1996;98:1493-1501.
5. Gasic GP, Arenas CP, Gasic GJ. Coagulation factors X, Xa, and protein S as potent mitogens of cultured aortic smooth muscle cells. Proc Natl Acad Sci U S A. 1992;89:2317-2320.
6. Bar-Shavit R, Benezra M, Eldor A, Hy-Am E, Fenton JW, Wilner GD. Thrombin immobilized to extracellular matrix is potent mitogen for vascular SMC: Nonenzymatic model of action. Cell Regul. 1990;1: 453-463.
7. Speidel CM, Eisenberg PR, Ruf W, Edgington TS, Abendschein DR. Tissue factor mediates prolonged procoagulant activity on the luminal surface of balloon-injured aortas in rabbits. Circulation. 1995;92: 3323-3330.
8. Marmur JD, Rossikhina M, Guha A, Fyfe B, Friedrich V, Mendlowitz M, Nemerson Y, Taubman MB. Tissue factor is rapidly induced in arterial smooth muscle after balloon injury. J Clin Invest. 1993;91:2253-2259.
9. Weiss HJ, Turitto VT, Baumgartner HR, Nemerson Y, Hoffman T. Evidence for the presence of tissue factor activity on subendothelium. Blood. 1989;73:968-975.
10. Oltrona L, Speidel CM, Recchia D, Wickline SA, Eisenberg PR, Abendschein DR. Inhibition of tissue factor-mediated coagulation markedly attenuates stenosis after balloon-induced arterial injury in minipigs. Circulation. 1997;96:646-652.
11. Jang Y, Guzman LA, Lincoff M, Gottsauner-Woff M, Ezban M, Ellis SG, Topol EJ. Influence of blockade at levels of coagulation cascade on restenosis in a rabbit atherosclerotic femoral artery injury model. Circulation. 1995;92:3041-3050.
12. Asada Y, Hara S, Tsuneyoshi A, Hatakeyama K, Kisanuki A, Marutsuka K, Sato Y, Kamikubo Y, Sumiyoshi A. Fibrin-rich and platelet-rich thrombus formation on neointima: recombinant tissue factor pathway inhibitor prevents fibrin formation and neointimal development following repeated balloon injury of rabbit aorta. Thromb Haemost. 1998;80: 506-511.
13. Ragosta M, Gimple LW, Gertz SD, Dunwiddie CT, Vlasuk GP, Haber HL, Powers ER, Roberts WC, Sarembock IJ. Specific factor Xa inhibition reduced restenosis after balloon angioplasty of atherosclerotic femoral arteries in rabbit. Circulation. 1994;89:1262-1271.
14. Sarembock IJ, Gertz SD, Gimple LW, Owen RM, Powers ER, Roberts WC. Effectiveness of recombinant desulphatohirudin in reducing restenosis after balloon angioplasty of atherosclerotic femoral arteries in rabbits. Circulation. 1991;84:232-243.
15. Hamamoto T, Yamamoto M, Nordfang O, Petersen JGL, Foster DC, Kisiel W. Inhibitory properties of full length and truncated recombinant tissue factor pathway inhibitor. J Biol Chem. 1993;268:8704-8710.
16. Wesselschmidt R, Likert K, Girard T, Wun TC, Broze GJ. Tissue factor pathway inhibitor: The carboxy-terminus is required for optimal inhibition of factor Xa. Blood. 1992;79:2004-2010.
17. Callander NS, Rao LVM, Nordfang O, Sandset PM, Warn-Cramer B, Rapaport SI. Mechanism of binding of recombinant extrinsic pathway inhibitor(rEPI) to cultured cell surfaces. Evidence that rEPI can bind to and inhibit factor VIIa-tissue factor complexes in the absence of factor Xa. J Biol Chem. 1992;267:876-882.
18. Girard TJ, Warren LA, Novotny WF, Likert KM, Brown SG, Miletich PJ, Broze GJ. Functional significance of the Kunitz-type inhibitory domains coagulation inhibitor. Nature. 1989;338:518-520.
19. Broze GJ, Warren LA, Novotny WF, Higuchi DA, Girard TJ, Miletich J. The lipoprotein-associated coagulation inhibitor that inhibits factor VII-tissue complex also inhibits Xa: Insight into its possible mechanism of action. Blood. 1988;71:335-343.
20. Warn-Cramer BJ, Rao LVM, Maki SL, Rapaport SI. Modifications of extrinsic pathway inhibitor(EPI) and factor Xa that affect their ability to interact and inhibit factor VIIa/tissue factor: Evidence for a two-step model of inhibition. Thromb Haemostas. 1988;60:453-456.
21. Ho G, Toomey JR, Broze GJ, Schwartz AL. Receptor-mediated endocytosis of coagulation factor Xa requires cell surface-bound tissue factor pathway inhibitor. J Biol Chem. 1996;271:9497-9502.
22. Sevinsky JR, Rao VM, Ruf W. Ligand-induced protease receptor translocation into caveolae: A mechanism for regulating cell surface proteolysis of the tissue factor-dependent coagulation pathway. J Cell Biol. 1996;133:293-304.
23. Mulder AB, Smit JW, Bom VJ, Blom NR, Halie MR, van der Meer J. Association of endothelial tissue factor and thrombomodulin with caveolae. Blood. 1996;88:3667-3670.
24. Sato Y, Asada Y, Marutsuka K, Hatakeyama K, Kamikubo Y, Sumiyoshi A. Tissue factor pathway inhibitor inhibits aortic smooth muscle cell migration induced by tissue factor/factor VIIa complex. Thromb Haemost. 1997;78:1138-1141.
25. Kamikubo Y, Nakahara Y, Takemoto S, Hamuro T, Miyamoto S, Funatsu A. Human recombinant tissue-factor pathway inhibitor prevents the proliferation of cultured human neonatal aortic smooth muscle cells. FEBS Lett. 1997;407:116-120.
26. Diaz-Collier JA, Palmier MO, Kretzmer KK, Bishop BF, Combs RG, Obukowicz MG, Frazier RB, Bild GS, Joy WD, Hill SR, Duffin KL, Gustafson ME, Junger KD, Grabner RW, Galluppi GR, Wun T. Refold and characterization of recombinant tissue factor pathway inhibitor expressed in Escherichia coli. Thromb Haemost. 1994;71:339-346.
27. Girard TJ, MacPhail LA, Likat KM, Novotny WF, Miletich JP, Broze GJ. Inhibition of factor VIIa-tissue factor coagulation activity by a hybrid protein. Science. 1990;248:1421-1424.
28. Broze GJ Jr, Majerus PW. Purification and properties of human coagulation factor VII. J Biol Chem. 1980;255:1242-1247.
29. Clowes AW, Reidy MA, Clawes MM. Kinetics of cellular proliferation after arterial injury. 1: Smooth muscle growth in the absence of endothelium. Lab Invest. 1983;49:327-333.
30. Baugh RJ, Broze GJ, Krishnaswamy S. Regulation of extrinsic pathway factor Xa formation by tissue factor pathway inhibitor. J Biol Chem. 1998;273:4378-4386.
31. Himber J, Kirchhofer D, Riederer M, Tschopp TB, Steiner B, Roux SP. Dissociation of antithrombotic effect and bleeding time prolongation in rabbits by inhibiting tissue factor function. Thromb Haemost. 1997;78: 1142-1149.
32. Harker LA, Hanson SR, Wilcox JN, Kelly AB. Antithrombotic and antilesion benefits without hemorrhagic risks by inhibiting tissue factor pathway. Haemostasis. 1996;26(Suppl 1):76-82.
33. Harker LA. New antithrombotic strategies for resistant thrombotic processes. J Clin Pharmacol. 1994;34:3-16.